International Prostate Cancer Update Archives

Putting Germline Testing into Context: A Primer and Current Knowledge

Posted by Alan H. Bryce, MD | Oct 2024

Alan H. Bryce, MD, explores the critical role of germline testing in prostate cancer, providing a primer on its current applications. He emphasizes identifying these genetic markers for patient management and familial risk assessment.

The 9-minute presentation considers the most relevant genes associated with prostate cancer risk, including BRCA1, BRCA2, and ATM. Dr. Bryce also highlights data problems with germline variants, questioning the representation of diverse racial and ethnic groups in clinical trials.

Presentations from 1st International Functional and Reconstructive Urology Update

Posted by David Utz | Sep 2024

These lectures were presented during the Presentations from 1st International Functional and Reconstructive Urology Update in August 2024, in Denver, Colorado.

Integrating Care in Advanced Prostate Cancer

Posted by John W. Davis, MD | Sep 2024

John W. Davis, MD, addresses the economic burden and stress experienced by patients due to high treatment costs in advanced prostate cancer (APC) management. He stresses that this aspect of APC care often goes under-discussed.

In this 11-minute presentation, Dr. Davis highlights direct costs such as medications, hospital stays, and physician fees, as well as indirect costs including lost income and travel expenses. He emphasizes that these financial strains can lead to treatment non-adherence, delayed care, and worsened clinical outcomes.

John W. Davis, MD, highlights the different ways integrated care models can be adopted across healthcare systems to enhance the management of advanced prostate cancer. By fostering a collaborative approach and eliminating barriers, Dr. Davis believes that the future of advanced prostate cancer care will be strengthened.

PARPi in mCRPC

Posted by Daniel P. Petrylak, MD | Sep 2024

Daniel P. Petrylak, MD, Yale University Cancer Center, New Haven, Connecticut, summarizes the current and future role of PARP inhibitors in mCRPC, providing valuable insights into their clinical application and potential to improve patient outcomes.

In this 9-minute presentation, Dr. Henderson highlights direct costs such as medications, hospital stays, and physician fees, as well as indirect costs including lost income and travel expenses. He emphasizes that these financial strains can lead to treatment non-adherence, delayed care, and worsened clinical outcomes.

Dr. Henderson discusses various strategies and interventions to address these challenges, underscoring the importance of policy changes at the institutional and governmental levels to improve access to affordable care.

Brian Moran Distinguished Lecture: Mobilizing Moran’s Army from Seed to Shining Seed

Posted by Peter F. Orio III, DO, MS | Sep 2024

Over the course of his career to date, Dr. Moran’s emphasis on quality of life issues and long-term outcomes for prostate cancer patients is evident, and his contributions to the fight against prostate cancer, such as performing over 30,000 prostate seed implant procedures and founding the Chicago Prostate Cancer Center, are innumerable.

Dr. Moran is a member of multiple specialty societies, including the American Society of Therapeutic Radiology and Oncology, the American College of Radiology, and the American Brachytherapy Society. To learn more about Dr. Moran, please visit his Author Page on Grand Rounds in Urology.

The inaugural lecture was given at IPCU 34 by Peter F. Orio III, DO, MS.